摘要:
Novel compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and X have the meaning indicated in claim 1, and their salts exhibit endothelin receptor-antagonistic properties.
摘要:
Novel compounds of the formula ##STR1## in which --Y--Z--, R.sup.1 R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X have the meaning indicated and their salts show endothelin receptor-antagonistic properties.
摘要:
Novel compounds of the formula I ##STR1## in which --Y--Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings as stated in the specification, and their salts show endothelin receptor antagonist properties.
摘要:
This invention relates to pyridizinone derivatives of formula I ##STR1## wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.
摘要:
The invention concerns compounds of formula (I),in which R is (i), (ii) or (iii); n is 0, 1 or 2; X means O or S; and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have different meanings, or a cyclized tautomeric shape. The invention also concerns the (E) isomers and salts of these compounds which display endothelin receptor antagonistic properties. ##STR1##
摘要:
Novel compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, --A.dbd.B--C.dbd.D--, Ar and X have the meaning indicated in claim 1, and their salts show endothelin receptor-antagonistic properties.
摘要:
Novel compounds of the formula I in which R is X is O or S, and R1, R2, R3, R4, R5 and R6 have the meaning indicated in patent claim 1, or a tautomeric ring-closed form, and the (E) isomers and their salts exhibit endothelin receptor-antagonistic properties.
摘要:
The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.
摘要:
Aminothiophenecarboxamides of the formula I ##STR1## and their physiologically acceptable salts, whereinR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, A and n have the meanings stated in claim 1, exhibit phosphodiesterase V inhibition and can be used for the treatment of diseases of the cardiovascular system and for the therapy of disturbances of potency.